nach oben

Erschienen in:

19.04.2016 | Review

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

verfasst von: Olof Eriksson, Maren Laughlin, Maarten Brom, Pirjo Nuutila, Michael Roden, Albert Hwa, Riccardo Bonadonna, Martin Gotthardt

Erschienen in: Diabetologia | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Radiotracer imaging is characterised by high in vivo sensitivity, with a detection limit in the lower picomolar range. Therefore, radiotracers represent a valuable tool for imaging pancreatic beta cells. High demands are made of radiotracers for in vivo imaging of beta cells. Beta cells represent only a small fraction of the volume of the pancreas (usually 1–3%) and are scattered in the tiny islets of Langerhans throughout the organ. In order to be able to measure a beta cell-specific signal, one has to rely on highly specific tracer molecules because current in vivo imaging technologies do not allow the resolution of single islets in humans non-invasively. Currently, a considerable amount of preclinical data are available for several radiotracers and three are under clinical evaluation. We summarise the current status of the evaluation of these tracer molecules and put forward recommendations for their further evaluation.

Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L (2014) The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383:1084–1094CrossRefPubMed

Krogvold L, Edwin B, Buanes T et al (2014) Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57:841–843CrossRefPubMed

Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10(Suppl 4):32–42CrossRefPubMed

Gotthardt M, Eizirik DL, Cnop M, Brom M (2014) Beta cell imaging - a key tool in optimized diabetes prevention and treatment. Trends Endocrinol Metab 25:375–377CrossRefPubMed

Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA (2004) Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 6:652–659CrossRefPubMed

Eriksson O, Espes D, Selvaraju RK et al (2014) Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 63:3428–3437CrossRefPubMed

Freeby M, Ichise M, Harris PE (2012) Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Islets 4:393–397CrossRefPubMedPubMedCentral

Karlsson F, Antonodimitrakis PC, Eriksson O (2015) Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers. Nucl Med Biol 42:762–769CrossRefPubMed

Maffei A, Liu Z, Witkowski P et al (2004) Identification of tissue-restricted transcripts in human islets. Endocrinology 145:4513–4521CrossRefPubMed

10.

Orlefors H, Sundin A, Garske U et al (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90:3392–3400CrossRefPubMed

11.

Mohnike K, Blankenstein O, Minn H, Mohnike W, Fuchtner F, Otonkoski T (2008) [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res 70:65–72CrossRefPubMed

12.

Eriksson O, Selvaraju RK, Johansson L et al (2014) Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med 55:460–465CrossRefPubMed

13.

Bennet H, Balhuizen A, Medina A et al (2015) Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 71:113–120CrossRefPubMed

14.

Schneider S, Feilen PJ, Schreckenberger M et al (2005) In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 113:388–395CrossRefPubMed

15.

Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS (2008) Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56:841–851CrossRefPubMedPubMedCentral

16.

Brom M, Woliner-van der Weg W, Joosten L et al (2014) Non-invasive quantification of the beta cell mass by SPECT with (111)In-labelled exendin. Diabetologia 57:950–959CrossRefPubMed

17.

Brom M, Joosten L, Frielink C, Boerman O, Gotthardt M (2015) (111)In-exendin uptake in the pancreas correlates with the beta-cell mass and not with the alpha-cell mass. Diabetes 64:1324–1328CrossRefPubMed

18.

Bouckenooghe T, Flamez D, Ortis F, Goldman S, Eizirik DL (2010) Identification of new pancreatic beta cell targets for in vivo imaging by a systems biology approach. Curr Pharm Des 16:1609–1618CrossRefPubMed

19.

Lindskog C, Korsgren O, Ponten F, Eriksson JW, Johansson L, Danielsson A (2012) Novel pancreatic beta cell-specific proteins: antibody-based proteomics for identification of new biomarker candidates. J Proteome 75:2611–2620CrossRef

20.

Nalin L, Selvaraju RK, Velikyan I et al (2014) Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs. Eur J Nucl Med Mol Imaging 41:1800–1810CrossRefPubMed

21.

Virostko J, Henske J, Vinet L et al (2011) Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proc Natl Acad Sci U S A 108:20719–20724CrossRefPubMedPubMedCentral

22.

Mikkola K, Yim CB, Fagerholm V et al (2014) 64Cu- and 68Ga-labelled [Nle(14), Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 16:255–263CrossRefPubMed

23.

Velikyan I, Bulenga TN, Selvaraju R et al (2015) Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. Am J Nucl Med Mol Imaging 5:109–126PubMedPubMedCentral

24.

Di Gialleonardo V, Signore A, Scheerstra EA et al (2012) 11C-hydroxytryptophan uptake and metabolism in endocrine and exocrine pancreas. J Nucl Med 53:1755–1763CrossRefPubMed

25.

Ekholm R, Ericson LE, Lundquist I (1971) Monoamines in the pancreatic islets of the mouse. Subcellular localization of 5-hydroxytryptamine by electron microscopic autoradiography. Diabetologia 7:339–348CrossRefPubMed

26.

Selvaraju RK, Velikyan I, Johansson L et al (2013) In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med 54:1458–1463CrossRefPubMed

27.

Singhal T, Ding YS, Weinzimmer D et al (2011) Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol 13:973–984CrossRefPubMed

28.

Eriksson O, Jahan M, Johnstrom P et al (2010) In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol 37:357–363CrossRefPubMed

29.

Goland R, Freeby M, Parsey R et al (2009) 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50:382–389CrossRefPubMedPubMedCentral

30.

Normandin MD, Petersen KF, Ding YS et al (2012) In vivo imaging of endogenous pancreatic beta-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 53:908–916CrossRefPubMedPubMedCentral

31.

Freeby MJ, Kringas P, Goland RS et al (2015) Cross-sectional and test-retest characterization of PET with [(18)F]FP-(+)-DTBZ for beta cell mass estimates in diabetes. Mol Imaging Biol 18:292–301CrossRefPubMedPubMedCentral

32.

Coppieters KT, Dotta F, Amirian N et al (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209:51–60CrossRefPubMedPubMedCentral

33.

Keenan HA, Sun JK, Levine J et al (2010) Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59:2846–2853CrossRefPubMedPubMedCentral

34.

Williams AJ, Thrower SL, Sequeiros IM et al (2012) Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 97:E2109–E2113CrossRefPubMed

35.

Henderson JR, Daniel PM, Fraser PA (1981) The pancreas as a single organ: the influence of the endocrine upon the exocrine part of the gland. Gut 22:158–167CrossRefPubMedPubMedCentral

36.

Mezza T, Kulkarni RN (2014) The regulation of pre- and post-maturational plasticity of mammalian islet cell mass. Diabetologia 57:1291–1303CrossRefPubMed

37.

Fagerholm V, Mikkola KK, Ishizu T et al (2010) Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 51:1439–1446CrossRefPubMed

38.

Harris PE, Farwell MD, Ichise M (2013) PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [(18)F]FP-DTBZ in baboons. Nucl Med Biol 40:60–64CrossRefPubMed

39.

Tsao HH, Skovronsky DM, Lin KJ, Yen TC, Wey SP, Kung MP (2011) Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas. Nucl Med Biol 38:1029–1034CrossRefPubMed

40.

Schafer MK, Hartwig NR, Kalmbach N et al (2013) Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models. Diabetologia 56:1047–1056CrossRefPubMedPubMedCentral

41.

Gianani R, Campbell-Thompson M, Sarkar SA et al (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53:690–698CrossRefPubMed

42.

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed

43.

Cnop M, Hughes SJ, Igoillo-Esteve M et al (2010) The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 53:321–330CrossRefPubMed

44.

Meier JJ, Butler AE, Saisho Y et al (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57:1584–1594CrossRefPubMedPubMedCentral

45.

Leeser DB, Bingaman AW, Poliakova L et al (2004) Pulsatile pump perfusion of pancreata before human islet cell isolation. Transplant Proc 36:1050–1051CrossRefPubMed

46.

Henquin JC, Rahier J (2011) Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 54:1720–1725CrossRefPubMedPubMedCentral

47.

Kou K, Saisho Y, Sato S, Yamada T, Itoh H (2014) Islet number rather than islet size is a major determinant of beta- and alpha-cell mass in humans. J Clin Endocrinol Metab 99:1733–1740CrossRefPubMed

48.

Maffi P, Balzano G, Ponzoni M et al (2013) Autologous pancreatic islet transplantation in human bone marrow. Diabetes 62:3523–3531CrossRefPubMedPubMedCentral

49.

Braun M, Wendt A, Karanauskaite J et al (2007) Corelease and differential exit via the fusion pore of GABA, serotonin, and ATP from LDCV in rat pancreatic beta cells. J Gen Physiol 129:221–231CrossRefPubMedPubMedCentral

50.

Mannucci E, Tesi F, Bardini G et al (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 17:336–342PubMed

51.

Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC (2010) 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 37:1345–1355CrossRefPubMedPubMedCentral

52.

Selvaraju RK, Velikyan I, Asplund V et al (2014) Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma. Nucl Med Biol 41:471–476CrossRefPubMed

53.

Korner M, Stockli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736–743CrossRefPubMed

54.

Kung MP, Hou C, Lieberman BP et al (2008) In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 49:1171–1176CrossRefPubMed

55.

Joosten L, Brom M, Bos D et al (2015) Non-invasive determination of the beta bell mass with ¹¹¹In-exendin-3 in a rat model of spontaneous type 1 diabetes. Diabetologia 58(Suppl 1):S101

56.

Mathijs I, Xavier C, Peleman C et al (2015) A standardized method for in vivo mouse pancreas imaging and semiquantitative beta cell mass measurement by dual isotope SPECT. Mol Imaging Biol 17:58–66CrossRefPubMed

57.

Souza F, Simpson N, Raffo A et al (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506–1513CrossRefPubMedPubMedCentral

Titel: In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use
verfasst von: Olof Eriksson
Maren Laughlin
Maarten Brom
Pirjo Nuutila
Michael Roden
Albert Hwa
Riccardo Bonadonna
Martin Gotthardt
Publikationsdatum: 19.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 7/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3959-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Is it worth treating gestational diabetes: if so, when and how?

A decrease in hepatic microRNA-9 expression impairs gluconeogenesis by targeting FOXO1 in obese mice

The zinc finger transcription factor PW1/PEG3 restrains murine beta cell cycling

Risk factors for gestational diabetes: is prevention possible?

Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Innere Medizin